Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.

Leukemia. 2014 Nov;28(11):2213-21. doi: 10.1038/leu.2014.128. Epub 2014 Apr 7.

PMID:
24705479
2.

Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK.

Blood. 2014 Feb 20;123(8):1218-28. doi: 10.1182/blood-2012-12-475194. Epub 2013 Dec 20.

3.

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.

Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, Wei A, Ramshaw HS, Powell JA, Lopez AF, Lewis ID, McCall MN, Lock RB.

Haematologica. 2015 Jul;100(7):914-26. doi: 10.3324/haematol.2014.113092.

4.

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

Xie LH, Biondo M, Busfield SJ, Arruda A, Yang X, Vairo G, Minden MD.

Blood Cancer J. 2017 Jun 2;7(6):e567. doi: 10.1038/bcj.2017.52.

5.

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB.

Cell Stem Cell. 2009 Jul 2;5(1):31-42. doi: 10.1016/j.stem.2009.04.018.

6.

AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.

Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.

J Hematol Oncol. 2015 Feb 28;8:18. doi: 10.1186/s13045-015-0109-5.

7.

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.

Blood. 2016 Jan 7;127(1):122-31. doi: 10.1182/blood-2014-05-575704. Epub 2015 Nov 3.

8.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

PMID:
28246194
9.

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.

Blood. 2013 Oct 31;122(18):3138-48. doi: 10.1182/blood-2012-12-474056. Epub 2013 Sep 12.

10.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.

Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. Erratum in: Blood. 2016 Nov 24;128(21):2585.

11.

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10786-91. doi: 10.1073/pnas.1422749112. Epub 2015 Aug 10.

12.

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.

Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH.

Br J Haematol. 2010 Sep;150(5):574-86. doi: 10.1111/j.1365-2141.2010.08300.x. Epub 2010 Jul 16.

PMID:
20636437
13.

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.

Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.

PLoS One. 2016 Aug 22;11(8):e0159477. doi: 10.1371/journal.pone.0159477. eCollection 2016.

14.

Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.

Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM.

J Nucl Med. 2011 Sep;52(9):1465-73. doi: 10.2967/jnumed.111.087668. Epub 2011 Aug 4.

15.

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.

Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US.

Blood. 2012 Mar 1;119(9):2074-82. doi: 10.1182/blood-2011-06-364521. Epub 2012 Jan 13.

16.

MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.

Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM.

Leuk Res. 2014 Nov;38(11):1367-73. doi: 10.1016/j.leukres.2014.09.005. Epub 2014 Sep 20.

PMID:
25278187
17.

Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.

Al-Mawali A, Gillis D, Lewis I.

J Hematol Oncol. 2016 Jul 27;9(1):61. doi: 10.1186/s13045-016-0292-z.

18.

Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.

Klöß S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, Granzin M, Gardlowski T, Matthies N, Soltenborn S, Schambach A, Koehl U.

Hum Gene Ther. 2017 Aug 15. doi: 10.1089/hum.2017.157. [Epub ahead of print]

PMID:
28810809
19.

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.

Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, Stockmeyer B, Mackensen A, Fey GH.

Br J Haematol. 2010 Mar;148(6):879-89. doi: 10.1111/j.1365-2141.2009.08033.x. Epub 2010 Jan 8.

PMID:
20064159
20.

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.

Leuk Lymphoma. 2015 May;56(5):1406-15. doi: 10.3109/10428194.2014.956316. Epub 2014 Nov 20.

PMID:
25248882

Supplemental Content

Support Center